Halozyme Therapeutics HALO Price / book
Price / book at other companies
Other financials
Where this comes from
Calculated from Halozyme Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's price / book.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's price / book?
- Halozyme Therapeutics (HALO) reported price / book of 34.9× in Q1 2026.
- How has Halozyme Therapeutics's price / book changed year-over-year?
- Halozyme Therapeutics's price / book increased by 113.3% year-over-year, from 16.3× to 34.9×.
- What is the long-term trend for Halozyme Therapeutics's price / book?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's price / book has grown at a 33.0% compound annual growth rate (CAGR), from 39× to 162.1×.
- What does price / book mean?
- How the market price compares to the company's accounting net worth.
- How do you interpret price / book?
- Below 1.0 can flag a market discount to book value (common for distressed or asset-heavy firms); high values reflect intangible value the balance sheet doesn't capture. Most informative for financials and asset-heavy businesses.
- How does price / book compare across companies?
- A core valuation gauge for banks and insurers; weak for asset-light firms where book value understates economic value.